Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration
NCT03558061
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Wet Age-related Macular Degeneration
Interventions
DRUG:
ALK4290
Sponsor
Alkahest, Inc.